Cubist Systematic Strategies, LLC Ventyx Biosciences, Inc. Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.31 - $5.59 $215,400 - $521,250	93,247 Added 165.76%	149,500 $345,000
Q1 2024 May 15, 2024	SELL	$1.9 - $10.13 $521,481 - $2.78 Million	-274,464 Reduced 82.99%	56,253 $309,000
Q4 2023 Feb 14, 2024	BUY	$2.08 - $31.18 $687,891 - $10.3 Million	330,717 New	330,717 $816,000
Q2 2023 Aug 14, 2023	BUY	$28.53 - $39.55 $119,226 - $165,279	4,179 New	4,179 $137,000
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $304,484 - $932,244	24,089 New	24,089 $841,000
Q2 2022 Aug 15, 2022	SELL	$11.95 - $18.75 $310 - $487	-26 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$10.0 - $19.98 $260 - $519	26 New	26 $0

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $144M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.